Conferences

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

01/24/2023

Excerpt from the Press Release: FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the…

Read More

Meet with Christopher Kata and the TrialStat team (booth # 906), during the SCOPE Summit, February 6th – 9th, in Orlando!

01/19/2023

Meet with Christopher Kata, Director of Sales & Marketing February 6th – 9th, 2023 at the SCOPE Summit for Clinical Operations Executives in Orlando, Florida. Christopher and the TrialStat team are exhibiting in booth # 906. Christopher Kata, Director of Sales & Marketing905 [email protected] Event: SCOPE – Summit for Clinical Operations Executives When: February 6th…

Read More

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

12/13/2022

-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured by best response- -Participants with TR-aGVHD (11 of 12 concomitant ruxolitinib) achieved an ORR of 67% and CR of 25% at Day 28- -Median survival benefits in TR-aGVHD participants compare favorably to historical controlsneihulizumab was well tolerated, with similar safety…

Read More

Meet with Christopher Kata during “CPHI Frankfurt”, on November 1st – 3rd!

10/21/2022

Meet in person with Christopher Kata during CPHI in Frankfurt, on November 1st to 3rd. If you’re attending be sure to reach out to Christopher to schedule a one on meeting! Each year CPHI unites more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities to network, identify business opportunities and expand the global…

Read More

Meet with Christopher Kata during the “CRAC – Future Considerations for Conducting Clinical Trials Meeting” November 17th!

10/20/2022

Christopher Kata is once again attending the CRAC – Future Considerations for Conducting Clinical Trials November 17th at the Markland Wood Golf Club. If you’re attending be sure to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher will be delivering a presentation titled “How To…

Read More

Meet with Christopher Kata during the “CTO 2022 – Clinical Trials Ontario Conference” November 10th – 11th!

10/12/2022

Christopher Kata is once again attending the CTO 2022 – Clinical Trials Ontario Conference on November 10th and 11th at the Hilton Toronto, 145 Richmond Street West, Toronto, ON, M5H 2L2. If you’re attending be sure to reach out to Christopher to schedule a one on meeting or search him out at the meeting! The CTO…

Read More

Meet with Christopher Kata during the “24th Annual SoCalBio Conference” October 6th to 7th!

10/04/2022

Christopher Kata is once again attending this years 24th Annual SocalBio Conference October 6th to 7th at the The West Long Beach. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher Kata, Director of Sales & Marketing905 [email protected] When:…

Read More

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

10/04/2022

Excerpt from the Press Release: MARLBOROUGH, Mass., Sept. 22, 2022 /PRNewswire/ — Phio Pharmaceuticals Corp. ( Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its research partner, Helmholtz Munich, presented preclinical data showing that Phio’s lead clinical product PH-762, an…

Read More

Meet with Christopher Kata during “SCDM 2022” September 11th to 13th!

08/15/2022

Christopher Kata and the TrialStat team are exhibiting at this years SCDM meeting on September 13th through the 16th in booth #400. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #400 at your convenience! Drop by for a chance to win…

Read More

Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting

08/10/2022

Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of ROS1-selective inhibitor NVL-520 Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 5, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced new preclinical data…

Read More